Ironwood Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Ironwood Pharmaceuticals, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Ironwood is positioned for revenue acceleration driven by LINZESS market leadership and pricing recovery, but faces execution risks with leverage and pipeline dependency on apraglutide success. The company expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion with total revenues of $450 to $475 million and.
What is Ironwood Pharmaceuticals, Inc.'s industry? Ironwood Pharmaceuticals, Inc. (ironwoodpharma.com) operates in Specialty Biotechnology/Pharmaceuticals - Gastrointestinal and Rare Diseases. AskCyborg classifies Ironwood Pharmaceuticals, Inc. under Specialty Biotechnology/Pharmaceuticals - Gastrointestinal and Rare Diseases in its company registry.
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, with LINZESS as the U.S. branded prescription ...
Cyborg Score thesis
Ironwood is positioned for revenue acceleration driven by LINZESS market leadership and pricing recovery, but faces execution...
Read the full analyst-debate transcript →Get the Latest Ironwood Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeIronwood Pharmaceuticals, Inc. Overview
Pro stress-test →Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, with LINZESS as the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The company expects LINZESS to return to blockbuster status in 2026 with over $1.1 billion in US net sales, driven by improved net price and low single-digit prescription demand growth. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support.
Strategic Profile
Pro stress-test →LINZESS delivered 11% EUTRx demand growth year-over-year in 2025, continuing to strengthen its position as the prescription market leader, surpassing 5.7 million unique patients treated since launch. In November, the FDA approved LINZESS for the treatment of IBS-C in patients aged 7 years of age and older, establishing it as the first and only prescription drug approved for this indication in patients 7-17 years old. Ironwood is in a much stronger financial position now, allowing it to leverage increased revenue and reduce debt, while remaining open to alternatives that could increase shareholder value.
Competitive Landscape
Pro stress-test →Ironwood maintains its position as the U.S. branded prescription market leader for IBS-C and CIC treatment with LINZESS. The company competes in the GI therapeutics space against specialty pharmaceutical and biotech firms developing alternative constipation and rare GI disease treatments. Primary competition comes from other GC-C agonists and emerging GLP-2 analogs, though LINZESS's extensive patient base and label expansion provide competitive moats.
Industry Context
Ironwood Pharmaceuticals, Inc. operates in Specialty Biotechnology/Pharmaceuticals - Gastrointestinal and Rare Diseases.
Key facts
Founded: 1998 · Headquarters: Boston, Massachusetts, USA · Revenue: $296M (2025) · Market cap: $616.55M